TY - JOUR
T1 - Optimizing stem cell transplantation in myelodysplastic syndromes
T2 - Unresolved questions
AU - Warlick, Erica D
PY - 2010/3/1
Y1 - 2010/3/1
N2 - Purpose of Review: Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative therapy for myelodysplastic syndrome (MDS). Recent efforts to optimize the curative potential of transplant have focused on pretransplant therapy options, the use of predictive models to improve patient selection, and transplant modifications using reduced conditioning intensity. This review highlights strategies to optimize transplant for MDS and identifies unresolved questions. Recent Findings: Debate surrounding pretransplant therapy and HCT conditioning intensity for MDS continues. The current literature fails to identify a superior pretransplant treatment regimen; however, for treated patients achieving complete remission, the data suggest that myeloablative conditioning may not be required for successful transplant outcomes. Patient selection for transplant is also critical, and predictive tools (WHO classification-based prognostic scoring system and hematopoietic cell transplantation comorbidity index) have helped identify patients who may derive the most transplant benefit. Summary: Prospective trials regarding optimal pretransplant therapy, utilization of patient selection tools, and conditioning intensity are warranted to improve transplant outcomes in MDS. Until those data are mature, current data suggest we initiate pretransplant therapy that minimizes toxicity and improves responses, try to optimize our patient selection using comorbidity (hematopoietic cell transplantation comorbidity index) and other predictive tools (WHO classification-based prognostic scoring system), and consider reduced intensity conditioning/nonmyeloablative conditioning in patients who have achieved a complete remission prior to transplant.
AB - Purpose of Review: Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative therapy for myelodysplastic syndrome (MDS). Recent efforts to optimize the curative potential of transplant have focused on pretransplant therapy options, the use of predictive models to improve patient selection, and transplant modifications using reduced conditioning intensity. This review highlights strategies to optimize transplant for MDS and identifies unresolved questions. Recent Findings: Debate surrounding pretransplant therapy and HCT conditioning intensity for MDS continues. The current literature fails to identify a superior pretransplant treatment regimen; however, for treated patients achieving complete remission, the data suggest that myeloablative conditioning may not be required for successful transplant outcomes. Patient selection for transplant is also critical, and predictive tools (WHO classification-based prognostic scoring system and hematopoietic cell transplantation comorbidity index) have helped identify patients who may derive the most transplant benefit. Summary: Prospective trials regarding optimal pretransplant therapy, utilization of patient selection tools, and conditioning intensity are warranted to improve transplant outcomes in MDS. Until those data are mature, current data suggest we initiate pretransplant therapy that minimizes toxicity and improves responses, try to optimize our patient selection using comorbidity (hematopoietic cell transplantation comorbidity index) and other predictive tools (WHO classification-based prognostic scoring system), and consider reduced intensity conditioning/nonmyeloablative conditioning in patients who have achieved a complete remission prior to transplant.
KW - Azacitidine
KW - Myelodysplastic syndrome
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=76749117155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76749117155&partnerID=8YFLogxK
U2 - 10.1097/CCO.0b013e328335a543
DO - 10.1097/CCO.0b013e328335a543
M3 - Review article
C2 - 20010295
AN - SCOPUS:76749117155
SN - 1040-8746
VL - 22
SP - 150
EP - 154
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
IS - 2
ER -